Title for Certificate
Credits
Which meeting are you claiming credit for?
*
Tuesday, March 17th – University of South Alabama
Friday, April 17th – Northwell Health
Thursday, April 23rd - Virtual (Multicenter)
Monday, May 4th – Cooper Health
Monday, June 8th - Tulane
Wednesday, June 24th - UNC
Thursday, June 25th - MUSC
Thursday, July 16th - NYU Langone
Wednesday, July 29th - OHSU
Thursday, September 10th - Albany Medical College
Friday, September 11th - Cedars-Sinai
Tuesday, September 22nd - University of Kentucky
Date 1
Date 2
Date 3
Date 4
Date 5
Date 6
Date 7
Date 8
Date 9
Date 10
Name
*
First Name
Last Name
Degree(s)
*
Email
*
example@example.com
Institution
Medical Speciality:
Neuromuscular
Neurology (Not neuromuscular)
Medicine
Other (Please specify)
Medical Profession:
Physician (Attending)
Physician (Fellow)
Physician (Resident)
Other (Please specify)
1. A patient develops weakness and numbness distally in the upper and lower limbs, evolving over a year. On examination, reflexes are reduced. Nerve conduction studies show absent motor and sensory responses in the lower limbs. The patient has diabetes, with a Hba1c of 7.0. There is no family history of neuropathy and no monoclonal gammopathy is present. A diagnosis of CIDP is most likely if:
*
a. Nerve conduction studies in the upper limbs show conduction velocity slowing, meeting the EAN/PNS criteria of demyelination
b. Nerve conduction studies in the upper limbs show reduced sensory responses, mildly slowed median motor conduction velocity, and CSF protein is elevated
c. Nerve conduction studies in the upper limbs show severe ulnar slowing across the elbow and median slowing across the wrist
d. Nerve conduction studies in the upper limbs are normal, but nerve biopsy of the sural nerve shows severe active axonal degeneration with chronic reinnervation changes
2. Which of the following findings provides the strongest evidence that CIDP is an antibody-mediated autoimmune disorder?
*
a. CIDP symptoms improve with corticosteroids
b. An IgG autoantibody can be detected in the majority of patients with CIDP
c. Passive transfer of IgG from patients with CIDP into animals may reproduce motor nerve conduction velocity
d. CIDP may present with multifocal, asymmetric weakness and numbness in the distribution of named nerves or plexus
3. A 61-year-old patient with CIDP has been treated with IVIg but struggles with the frequency and tolerability of the infusions. You discuss efgartigimod therapy and the ADHERE trial. Which of the following best summarizes the main finding of ADHERE?
*
a. Most patients required additional IVIg during the trial despite efgartigimod treatment
b. Efgartigimod significantly reduced relapse risk in patients who responded to an initial treatment course
c. The study showed that efgartigimod was only effective in CIDP patients that had not previously been treated with IVIG or corticosteroids
d. Efgartigimod resulted in less disability, but was frequently discontinued due to poor tolerability
4. A 52-year-old patient with newly diagnosed CIDP has progressive symmetric weakness and areflexia. Nerve conduction studies show demyelinating features. The patient is concerned about long-term medication side effects, dislikes frequent hospital visits, and works a job that makes monthly infusions difficult. They ask about treatment options and want to be actively involved in choosing a treatment plan. Which of the following is the best next step in management?
*
a. Select oral corticosteroids because they are inexpensive and effective in most patients
b. Start IVIg because it has the strongest evidence base and is well tolerated in most patients
c. Recommend FcRn inhibitor therapy to reduce clinic visits
d. Explain the benefits, risks, logistics, and uncertainties of corticosteroids, IVIg, and FcRn inhibitor therapy, and incorporate the patient’s values and preferences into the treatment choice
e. Delay treatment until symptoms worsen to avoid exposing the patient to medication risks
Learning Objectives
Rows
Poor
Fair
Good
Very Good
Excellent
Examine the pathophysiology of CIDP to be current with the science and targeted therapies for CIDP
Accurately diagnose CIDP using PNS/EAN guidelines, clinical symptoms, nerve conduction study findings, and other supportive criteria
Evaluate the latest clinical trial data for current therapies, including FcRn blockers, to treat patients with CIDP
Review optimal treatment plans to apply the most effective strategies that may include FcRn blockers and the role of self- administration syringes
Do you feel this activity was fair balanced and free of commercial bias?
Yes
No
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
Yes
No
N/A
This educational activity will result in a change in my practice behavior.
Yes
No
N/A
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
I gained new strategies/skills/information that my team can apply to practice
I plan to implement new strategies/skills/information in my practice
I will be more competent in my team’s management of patient care
I will improve my communication with the healthcare team
What factors beyond clinical care that effect the health of your patients does your team experience?
Submit
Should be Empty: